Second attempt to discontinue imatinib in CP-CML patients with a second sustained complete molecular response

Blood

Volumn 120, Issue 9, 2012, Pages 1959-1960

  Legros, Laurence ^a,b   Rousselot, Philippe ^c   Giraudier, Stéphane ^d   Tulliez, Michel ^d   Huguet, Françoise ^e   Nicolini, Franck Emmanuel ^f   Mahon, Francois Xavier ^g  

^a CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

^b CNRS   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

^d HENRI MONDOR HOSPITAL   (France)

^e CHU PURPAN   (France)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; DASATINIB; IMATINIB;

CANCER RECURRENCE; CHRONIC MYELOID LEUKEMIA; DRUG WITHDRAWAL; FEASIBILITY STUDY; FOLLOW UP; HUMAN; LETTER; PRIORITY JOURNAL; SEX RATIO; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84865776165     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-408229     Document Type: Letter

References (1)

1. Mahon FX, Rea D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029-1035.